Trukhina D A, Mamedova E O, Nikitin A G, Koshkin P A, Belaya Zh E, Melnichenko G A
Endocrinology Research Centre.
Pulmonology Scientific Research Institute under FMBA of Russia.
Probl Endokrinol (Mosk). 2024 Jan 24;69(6):70-85. doi: 10.14341/probl13357.
MEN-1 is a rare autosomal dominant disease caused by mutations in MEN1 gene encoding the menin protein. This syndrome is characterized by the occurrence of parathyroid tumors, gastroenteropancreatic neuroendocrine tumors, pituitary adenomas, as well as other endocrine and non-endocrine tumors. If a patient with the MEN-1 phenotype carry no mutations in the MEN1 gene, the condition considers a phenocopy of syndrome (phMEN1). The possible cause of this changes could be changes in epigenetic regulation, particularly in microRNA expression that might affect menin signaling pathways.
to identify differently expressed circulating miRNAs in plasma in patients with genetically confirmed MEN-1 syndrome, its phenocopies and healthy controls.
single-center, case-control study was conducted. We assessed plasma microRNA expression in patients with genetically confirmed MEN-1 (gMEN1), phMEN1 and healthy controls. Morning plasma samples were collected from fasting patients and stored at -80°C. Total RNA isolation was performed using miRNeasy Mini Kit with QIAcube. The libraries were prepared by the QIAseq miRNA Library Kit following the manufacturer. Circulating miRNA sequencing was done on Illumina NextSeq 500 (Illumina). Subsequent data processing was performed using the DESeq2 bioinformatics algorithm.
we enrolled 21 consecutive patients with gMEN1 and 11 patients with phMEN1, along with 12 gender matched controls. Median age of gMEN1 was 38,0 [34,0; 41,0]; in phMEN1 - 59,0 [51,0; 60,0]; control - 59,5 [51,5; 62,5]. The gMEN1 group differed in age (p<0.01) but not gender (р=0.739) or BMI (р=0.116) compared to phMEN1 and controls group, the last two groups did not differ by these parameters (p>0.05). 25 microRNA were differently expressed in groups gMEN1 and phMEN1 (21 upregulated microRNAs, 4 - downregulated). Comparison of samples from the phMEN-1 group and relatively healthy controls revealed 10 differently expressed microRNAs: 5 - upregulated; 5 - downregulated. In the gMEN-1 and control groups, 26 differently expressed microRNAs were found: 24 - upregulated; 2 - downregulated. The miRNAs most differing in expression among the groups were selected for further validation by RT-qPCR (in the groups of gMEN1 vs phMEN1 - miR-3613-5p, miR-335-5p, miR-32-5p, miR-425-3p, miR-25-5p, miR-576-5p, miR-215-5p, miR-30a-3p, miR-141-3p, miR-760, miR-501-3p; gMEN1 vs control - miR-1976, miR-144-5p miR-532-3p, miR-375; as well as in phMEN1 vs control - miR-944, miR-191-5p, miR-98-5p).
In a pilot study, we detected microRNAs that may be expressed differently between patients with gMEN-1 and phMEN-1. The results need to be validated using different measurement method with larger sample size.
多发性内分泌腺瘤1型(MEN-1)是一种罕见的常染色体显性疾病,由编码menin蛋白的MEN1基因突变引起。该综合征的特征是甲状旁腺肿瘤、胃肠胰神经内分泌肿瘤、垂体腺瘤以及其他内分泌和非内分泌肿瘤的发生。如果具有MEN-1表型的患者在MEN1基因中没有突变,则该病症被认为是该综合征的拟表型(phMEN1)。这种变化的可能原因可能是表观遗传调控的改变,特别是可能影响menin信号通路的微小RNA表达的变化。
鉴定基因确诊的MEN-1综合征患者、其拟表型患者和健康对照者血浆中差异表达的循环微小RNA。
进行了一项单中心病例对照研究。我们评估了基因确诊的MEN-1(gMEN1)、phMEN1患者和健康对照者的血浆微小RNA表达。从空腹患者采集早晨血浆样本并储存在-80°C。使用带有QIAcube的miRNeasy Mini试剂盒进行总RNA分离。按照制造商说明使用QIAseq miRNA文库试剂盒制备文库。在Illumina NextSeq 500(Illumina)上进行循环微小RNA测序。随后使用DESeq2生物信息学算法进行数据处理。
我们纳入了21例连续的gMEN1患者和11例phMEN1患者,以及12例性别匹配的对照者。gMEN1患者的中位年龄为38.0[34.0;41.0];phMEN1患者为59.0[51.0;60.0];对照者为59.5[51.5;62.5]。与phMEN1组和对照组相比,gMEN1组在年龄上有差异(p<0.01),但在性别(p=0.739)或体重指数(p=0.116)上无差异,后两组在这些参数上无差异(p>0.05)。gMEN1组和phMEN1组中有25种微小RNA差异表达(21种上调的微小RNA,4种下调的)。phMEN-1组与相对健康的对照组样本比较显示有10种差异表达的微小RNA:5种上调;5种下调。在gMEN-1组和对照组中,发现26种差异表达的微小RNA:24种上调;2种下调。选择各组中表达差异最大的微小RNA通过逆转录定量聚合酶链反应进行进一步验证(在gMEN1与phMEN1组中为miR-3613-5p、miR-335-5p、miR-32-5p、miR-425-3p、miR-25-5p、miR-576-5p、miR-215-5p、miR-30a-3p、miR-141-3p、miR-760、miR-501-3p;gMEN1与对照组中为miR-1976、miR-144-5p、miR-532-3p、miR-375;以及phMEN1与对照组中为miR-944、miR-191-5p、miR-98-5p)。
在一项初步研究中,我们检测到gMEN-1和phMEN-1患者之间可能差异表达的微小RNA。结果需要使用不同测量方法并扩大样本量进行验证。